Evoke plans to price IPO of stock between $12.00 and $14.00 per share

Proceeds used for research and development activities for EVK-001

By Devika Patel

Knoxville, Tenn., Aug. 30 - Evoke Pharma, Inc. will sell 2.1 million common shares in its initial public offering of common stock, according to a Form S-1 filed Friday with the Securities and Exchange Commission. The deal, which was announced on May 24, will have a 30-day greenshoe option of 315,000 additional shares and is being conducted on a firm commitment basis.

The shares will be sold at a price expected to be between $12.00 and $14.00 per share.

Aegis Capital Corp. is the bookrunner. Cantor Fitzgerald & Co. and Feltl and Co. are the co-managers.

Proceeds will be used for research and development activities for EVK-001 and for working capital and other general corporate purposes.

The specialty pharmaceutical company is based in San Diego. The company expects its shares will trade on the Nasdaq under the symbol "EVOK."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.